The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, and Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

The Global Diabetes Devices Market is expected to grow at a rate of ~6% by 2026. The growing prevalence of diabetes, increasing health consciousness & awareness regarding diabetes, rising prevalence of obesity and unhealthy eating habits among the population, technological advancements in diabetes monitoring devices, and increasing adoption of insulin delivery devices are some of […]

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The Diabetes Care Devices Market is Segmented by Management Devices (Insulin Pumps, Insulin Syringes, and More), Monitoring Devices (Self-Monitoring Blood Glucose and Continuous Glucose Monitoring), by Patient Type (Type-1 Diabetes, Type-2 Diabetes and More), by End User (Hospitals & Clinics, Home-Care Settings and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD) and Volume (units).

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Attributes	Description
Estimated Global Diabetes Care Devices Market Size (2024E)	USD 64.5 billion
Projected Global Diabetes Care Devices Market Value (2034F)	USD 117.7 billion
Value-based CAGR (2024 to 2034)	6.2%

Semi-annual Industry Update

Particular	Value CAGR
H1	5.7% (2023 to 2033)
H2	5.2% (2023 to 2033)
H1	4.5% (2024 to 2034)
H2	4.2% (2024 to 2034)

Country-wise Insights

Countries	CAGR 2024 to 2034
India	8.8%
China	8.4%
South Korea	8.1%
Australia	6.7%
France	4.3%
United States	3.4%

Category-wise Insights

Segment	Glucose Monitoring Devices (Product Type)
Value Share (2024)	58.3%

Segment	Diabetes Type II (Indication)
Value Share (2024)	19.7%

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

U.S. Diabetes Devices Market is size is valued at USD 44.36 Billion by 2032 and CAGR 6.5% Market by Indications by Distribution Channels.

Diabetes Devices Market was valued at USD 32.63 Billion in 2024 and is projected to reach USD 48.03 Billion by 2031, growing at a CAGR of 5.46% from 2024 to 2031.

Diabetes Devices Market Drivers

The Diabetes Devices Market is driven by several key factors:

Rising Prevalence of Diabetes: The increasing prevalence of diabetes globally, driven by factors like obesity, sedentary lifestyles, and aging populations, is a major driver.

Technological Advancements: Continuous advancements in diabetes care technology, such as continuous glucose monitoring (CGM) systems, insulin pumps, and automated insulin delivery systems, are improving diabetes management and patient outcomes.

Focus on Improved Disease Management: There's a growing emphasis on improving diabetes management to prevent complications like heart disease, kidney disease, and nerve damage.

Government Initiatives: Government initiatives to improve diabetes care and support innovation in diabetes technology are driving market growth.

Increased Patient Awareness: Growing awareness among patients about the benefits of advanced diabetes technologies, such as improved glycemic control and enhanced quality of life, is driving demand for these devices.

The Wearable Diabetes Devices Market report segments the industry into Device (Continuous Glucose Monitoring Devices, Insulin Pumps), Type (Non-Invasive Glucose Monitoring Devices, Invasive Glucose Monitoring Devices), End User (Hospital/Clinics, Home/Personal), and Geography (North America, Europe, Latin America, Asia-Pacific, Middle East and Africa). Get five years of historical data and market forecasts.

The global diabetes devices market size surpassed USD 33.55 billion in 2024 and is projected to witness a CAGR of over 7.5%, crossing USD 85.9 billion revenue by 2037. Insulin Delivery Devices segment is expected to dominate largest share by 2037, attributed to rising diabetic cases and increasing demand for homecare products and therapies.

The global diabetes devices market is experiencing robust growth, driven by the increasing prevalence of diabetes worldwide and the rising adoption of advanced technologies for diabetes management. The market, estimated at $XX billion in 2025, is projected to expand at a CAGR of XX% from 2025 to 2033, reaching a value of approximately $YY billion by 2033 (Note: XX and YY represent estimated values based on reasonable industry projections given the provided CAGR and typical market growth for medical devices; exact figures require full dataset). Key drivers include the growing geriatric population, increased awareness about diabetes management, technological advancements leading to more accurate and convenient monitoring devices (like continuous glucose monitors), and the rising preference for insulin pumps over traditional injection methods. Furthermore, the shift towards personalized medicine and the development of connected devices integrating data analysis and remote monitoring capabilities are significantly propelling market expansion. However, high costs associated with advanced diabetes devices, particularly continuous glucose monitors and insulin pumps, pose a significant restraint to market growth, particularly in developing economies. Variations in healthcare reimbursement policies across different regions also present challenges. The market is segmented by device type (e.g., insulin delivery systems, blood glucose monitoring systems, continuous glucose monitoring systems), by end-user (hospitals, clinics, homecare settings), and by region (North America, Europe, Asia-Pacific, etc.). Major players like Medtronic, Sanofi, Bayer, Becton Dickinson, Novo Nordisk, Abbott Laboratories, Roche, Lifescan, B. Braun, Dexcom, and Ypsomed Holdings are actively engaged in research and development, strategic partnerships, and acquisitions to expand their market share and offer innovative solutions. The competitive landscape is characterized by technological advancements, product differentiation, and an increasing focus on improving patient outcomes through integrated care solutions.

The Diabetes Devices Market size is expected to reach a valuation of USD 63.0 billion in 2033 growing at a CAGR of 8.00% . The Diabetes Devices Market research report classifies market by share, trend, demand, forecast and based on segmentation.

Planned monitoring requirements combined with insulin requirements for diabetic pets among dogs and cats create a market need for specialized care devices. Pixel GPS medicine forecasts the market to achieve USD 2,594 million in 2025 but predicts an increase to USD 4,645.5 million by 2035 at a compound annual growth rate (CAGR) of 6%.

Metric	Value
Industry Size (2025E)	USD 2,594 million
Industry Value (2035F)	USD 4,645.5 million
CAGR (2025 to 2035)	6%

Country-Wise Outlook

Country	CAGR (2025 to 2035)
USA	6.4%

Country	CAGR (2025 to 2035)
UK	5.8%

Region	CAGR (2025 to 2035)
European Union	6.0%

Country	CAGR (2025 to 2035)
Japan	5.6%

Country	CAGR (2025 to 2035)
South Korea	6.2%

Segmentation Outlook - Pet Diabetes Care Devices Market

Device Type	Market Share (2025)
Glucose Monitoring Devices	57.9%

End-User Segment	Market Share (2025)
Veterinary Clinics	46.4%

Competitive Outlook

Company Name	Estimated Market Share (%)
Zoetis Inc.	20-24%
Trividia Health, Inc. (PetTest)	15-19%
Merck Animal Health	12-16%
UltiMed, Inc.	8-12%
i-SENS, Inc.	5-9%
Other Companies (combined)	30-40%

Diabetes Devices Market is anticipated to grow at a CAGR of 8.1% during the forecast period, with an estimated size and share exceeding USD 67.39 billion by 2034.

Recent developments include: February 2024: DexCom introduced its real-time continuous glucose monitoring (CGM) system Dexcom ONE+ in Spain, Belgium, and Poland. Additionally, the company announced that the device is scheduled to be released in the Netherlands during the week commencing 12 February. Dexcom stated that Dexcom ONE+ will be launched in the Middle East, Africa, and various other European nations in the upcoming months., November 2022: The Eversense E3 continuous glucose monitor (CGM) was approved by the FDA and it received a CE Mark approval in Europe for people with diabetes aged 18 and older., June 2022: Senseonics received a CE mark for a 6-month CGM implant. Ascensia Diabetes Care, which signed up to sell Eversense in 2020, was expected to distribute the diabetes device in countries including Germany, Italy, and Spain, where it was laying the groundwork for launch through sales conferences and changes to its distribution model.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Monitoring Devices Hold Highest Market Share in Spain Diabetes Care Devices Market in the current year.

The Diabetes Devices Market size was valued at USD 32.70 billion in 2023 and is projected to reach USD 54.07 billion by 2032, exhibiting a CAGR of 7.45 % during the forecasts period. The Diabetes Devices Market refers to the products and instruments that are used to monitor and address the issue of high blood sugar in diabetes patients. Some of the products that are involved in this market include blood glucose meters, continuous glucose monitoring systems, insulin pumps, insulin pens, and lancing devices. These devices aid in the optimal regulating of blood glucose levels, injecting insulin, and generally controlling diabetes. Special emphasis is laid on the fact that applications are used at home care hospitals and clinics. Recent developments emphasize predictors, specifically the incorporation of artificial intelligence, mHealth applications, distributed databases for actual-time tracking, and individualized consideration. Also increasingly being seen in the market are a lot of products for minimally invasive or fully non-invasive treatments, which shows a growing trend toward making patients amenable to observing the necessary regimen for diabetes. Recent developments include: In May 2023, Medtronic has reached an agreement to purchase EOFlow, a manufacturer of insulin devices. Integrating EOFlow with Medtronic's Meal Detection Technology algorithm and advanced continuous glucose monitor (CGM) is anticipated to enhance the company's capacity to serve a broader range of people with diabetes , In April 2023, Undbio disclosed its intention to invest USD 100 million in constructing a US-based insulin manufacturing plant. The South Korean firm plans to establish a new facility in West Virginia to produce insulin and distribute its products within the country , In July 2023, CharmHealth and Bioverge have jointly invested in My Diabetes Tutor, a startup dedicated to improving the lives of individuals with diabetes .

Japan diabetes devices market size reached USD 1,936 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,487 Million by 2033, exhibiting a growth rate (CAGR) of 2.8% during 2025-2033. Significant innovations and technological advancements, focused on addressing the multifaceted demands of diabetic management, monitoring, and treatment are primarily driving the market growth.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 1,936 Million
Market Forecast in 2033	USD 2,487 Million
Market Growth Rate (2025-2033)	2.8%

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on type and distribution channel.

The size of the Wearable Diabetes Devices Market was valued at USD 11 Million in 2023 and is projected to reach USD 20 Million by 2032, with an expected CAGR of > 10.00% during the forecast period. The wearable diabetes devices market is primarily concerned with small devices that can be carried on the body, to assist patients with diabetes in controlling their glucose intake. Such devices include CGMs, insulin pumps and smart insulin pens, which are designed a real time monitoring and automation in the management of diabetes. They enable monitoring of glucose level from time to time and administration of insulin when it is required thereby reducing complications. Some of the trends are smart devices, artificial intelligence especially in decision making, mobile applications that enhance patient relation and cloud enabled solutions that enables distant monitoring. Public awareness and rise in the number of diabetics, advancement in technology and its acceptance contributes to the demand of these technological …in the advanced and developed regions due to availability of innovation coupled with supporting health care structures. Recent developments include: May 2023: The Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software have been granted clearance by the U.S. Food and Drug Administration for individuals aged six and above who have type 1 diabetes. When combined with a compatible FDA-cleared integrated continuous glucose monitor (iCGM), these two devices will create a novel system known as the iLet Bionic Pancreas. This innovative automated insulin dosing (AID) system employs an algorithm to ascertain and direct the administration of insulin., March 2023: The FDA has approved the Eversense E3 Continuous Glucose Monitoring (CGM) System. This innovative system offers real-time monitoring of blood sugar (glucose) levels and tracks their trends over time. Users can conveniently access this information through a mobile app installed on their smartphone, tablet, or other compatible device.. Key drivers for this market are: Rapidly Increasing Incidence and Prevalence of Diabetes, Technological Advancements in the Market. Potential restraints include: Monopolized Supply Chain and High Cost of Devices. Notable trends are: Rising diabetes prevalence globally is driving the market in forecast years.

The Diabetes Devices market is projected to be valued at $10 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 8%, reaching approximately $21 billion by 2034.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by rising diabetes prevalence, technological advancements in continuous glucose monitoring (CGM) systems, and increasing demand for convenient and effective diabetes management solutions. The market, valued at approximately $25.16 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors. Firstly, the aging population and increasing sedentary lifestyles contribute significantly to the surge in diabetes cases, creating a larger patient base requiring these devices. Secondly, the continuous innovation in CGM technology, offering real-time glucose monitoring and improved accuracy, is transforming diabetes management. These advancements are driving adoption rates and market expansion. Thirdly, the growing awareness of the importance of proactive diabetes management and self-care is influencing individual choices regarding devices and treatment strategies. While the market demonstrates substantial growth potential, certain factors could restrain its expansion. These include high device costs, particularly for advanced technologies like insulin pumps and CGM systems, which may limit accessibility for some patients. Furthermore, reimbursement policies and insurance coverage can impact market penetration, particularly in regions with limited healthcare access. The market is segmented into self-monitoring blood glucose (SMBG) devices (including glucometers, test strips, and lancets), continuous glucose monitoring (CGM) devices, and insulin delivery devices (such as insulin pumps, syringes, pens, and jet injectors). Competitive landscape analysis reveals key players such as Abbott, Dexcom, Medtronic, and Novo Nordisk, each contributing significantly to market share across various device categories. The North American region, specifically the United States, is expected to maintain a dominant market share owing to its advanced healthcare infrastructure, high diabetes prevalence, and strong regulatory support for innovative medical technologies. The future of the US diabetes devices market appears bright, with continued growth anticipated across various segments, driven by technological advancements, increasing awareness, and a growing patient population. However, addressing affordability and accessibility concerns remains crucial for ensuring market expansion and improved patient outcomes. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Notable trends are: Growing Diabetes and Obesity Population in the United States.